Virology Contract Research Laboratory

Specialized team of scientists

BSL 2 & BSL 3 Facilities

Leading in Influenza

and other targets: RSV, MERS, Rabies

and other targets: Polio, Rhino, Entero

Large Scale Diagnostic Services

Specialized Consultancy Services

NEWS

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology.
The ViroSpot assay platform is currently available for influenza virus and RSV, and under development for multiple other viral targets.

Virology Contract Research Laboratory

Specialized team of scientists

BSL 2 & BSL 3 Facilities

Leading in Influenza

and other targets: ZIKA, Dengue, Chikungunya

and other targets: VZV, HSV, HPV

Large Scale Diagnostic Services

Specialized Consultancy Services

NEWS

ViroSpot MN assay, a novel tool for antigenic characterization of influenza viruses and serology.
The ViroSpot assay platform is currently available for influenza virus and RSV, and under development for multiple other viral targets.

9th Annual Vaccine World Summit 2019

Our Contribution

 

During the conference, Viroclinics Biosciences’ experts will shed light on the topic: “Animal models to evaluate countermeasures against Influenza viruses”, during our presentation slot on February 13th.

The ongoing emergence of influenza viruses in humans and animals, through mechanisms of antigenic drift, shift and interspecies transmission, calls for the use of animal models that can rapidly address pathogenesis and transmission characteristics of influenza, as well as evaluate preventive and therapeutic intervention strategies.

Several animal models for influenza are currently available, including mice, guinea pigs, ferrets, cats, pigs and non-human primates. All animal models have their intrinsic pros and cons, and the research question addressed therefore basically determines the choice of the animal model.

More than one animal model may be used for the evaluation of intervention strategies for influenza. Commonly, novel generations of vaccines and antiviral strategies are tested for safety and efficacy in rodents, ferrets or macaques. The advantages and limitations of each of the available animal models, especially in the light of developing the highly desirable universal influenza vaccines, will be highlighted in this overview. 

Furthermore, we will present our views on how R&D outsourcing can stimulate the innovation processes for vaccine developers. Practical case examples will be discussed and new horizons will be explored by sharing our latest insights on Influenza, and other viral targets.

We are looking forward to sharing our latest insights with you during the 9th Annual Vaccine World Summit 2019.

 

Speaker

Dr Koert Stittelaar, Director Preclinical Services

Dr Koert Stittelaar joined Viroclinics Biosciences in 2006. Previous to this he was a Postdoc at the Virology Department at Erasmus MC Rotterdam in vaccine and pathogenesis research projects including HIV, dengue and poxvirus preclinical research. Koert was trained in medical microbiology at the National Institute of Public Health and University of Utrecht working on Neisseria meningitidis-specific T cell responses. Koert defended his PhD thesis in 2001: “Vaccination against Measles” at the Erasmus University Rotterdam. His start at Viroclinics Biosciences boosted the Preclinical Service activities within the company. He gained expertise in the field of influenza virus and RSV intervention strategy research and is now mainly concerned with containment of highly pathogenic viruses, model development and project acquisition like polio virus related projects. Koert has authored many publications.

Contact Speaker

OUR LATEST NEWS

↓